Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | YARS1 | P54577 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238987 | 1.00 | SLC7A5 (0.63) | SLC7A5OPRD1OPRM1OPRK1YARS1 | |
| SCHEMBL4018497 | 1.00 | SLC7A5 (0.63) | SLC7A5OPRD1OPRM1OPRK1YARS1 | |
| SCHEMBL4018493 | 1.00 | SLC7A5 (0.63) | SLC7A5OPRD1OPRM1OPRK1YARS1 | |
| SCHEMBL10716722 | 0.97 | OPRD1 (0.61) | SLC7A5OPRD1OPRM1OPRK1YARS1 | |
| SCHEMBL10716732 | 0.97 | OPRD1 (0.61) | SLC7A5OPRD1OPRM1OPRK1YARS1 | |
| SCHEMBL10621141 | 0.97 | OPRD1 (0.61) | SLC7A5OPRD1OPRM1OPRK1YARS1 | |
| SCHEMBL29822851 | 0.93 | OPRD1 (0.64) | SLC7A5OPRD1OPRM1OPRK1YARS1 | |
| SCHEMBL22644029 | 0.92 | OPRD1 (0.55) | SLC7A5OPRD1OPRM1OPRK1YARS1 | |
| SCHEMBL30792491 | 0.91 | OPRD1 (0.53) | SLC7A5OPRD1OPRM1OPRK1YARS1 | |
| SCHEMBL29431826 | 0.91 | OPRD1 (0.55) | SLC7A5OPRD1OPRM1OPRK1YARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504166-A1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF ITCHY DRY SKIN | MC2 Therapeutics Limited (GB) | 2025-02-12 | — | — | EP | claimed |
| CN-118620029-B | Dry-cured ham-derived DPP-IV (dipeptidyl peptidase IV) inhibitory peptide as well as preparation method, identification method and application thereof | 合肥工业大学 | 2024-12-20 | — | — | CN | claimed |
| CN-118984702-A | Topical preparation for treating or preventing dry skin itch | MC2疗法有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-117659116-B | Preparation method of tyrosine oligopeptide | 珠海瑞德林生物有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-20230414699-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2023-12-28 | — | — | US | claimed |
| WO-2023194400-A1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF ITCHY DRY SKIN | MC2 THERAPEUTICS LTD (GB) | 2023-10-12 | — | — | WO | claimed |
| EP-4225293-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 Therapeutics Limited (GB) | 2023-08-16 | — | — | EP | claimed |
| CN-116322671-A | Treatment of dermatological disorders | MC2疗法有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-108883149-B | Prevention and treatment of neurodegenerative diseases by ligand binding to the P62ZZ domain or arginylated BIP-mediated autophagy activity | 奧土择破利悟 | 2022-06-14 | — | — | CN | claimed |
| WO-2022074228-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2022-04-14 | — | — | WO | claimed |
| EP-0412061-B1 | 2-(N-acyl)amino-6,7-dimethoxy tetralines, process for their preparation and pharmaceutical compositions having antihypertensive activity containing same | SIGMA TAU IND FARMACEUTI (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0412061-A2 | 2-(N-acyl)amino-6,7-dimethoxy tetralines, process for their preparation and pharmaceutical compositions having antihypertensive activity containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1991-02-06 | — | — | EP | claimed |
| JP-62033180-A | — | — | None | — | — | JP | disclosed |
| EP-4504166-B1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF ITCHY DRY SKIN | MC2 THERAPEUTICS LTD (GB) | 2026-04-29 | — | — | EP | disclosed |
| EP-4733313-A2 | MACROCYCLIC MODULATORS OF DISEASE ASSOCIATED PROTEIN MISFOLDING AND AGGREGATION | ResQ Biotech P.C. (GR) | 2026-04-29 | — | — | EP | disclosed |
| EP-0154234-A2 | Substituted tyrosil alanine dipeptide amides | G.D. Searle & Co. (US) | 1985-09-11 | — | — | EP | disclosed |
| EP-0154234-A2 | Substituted tyrosil alanine dipeptide amides | G.D. Searle & Co. (US) | 1985-09-11 | — | — | EP | disclosed |
| EP-0154234-A2 | Substituted tyrosil alanine dipeptide amides | G.D. Searle & Co. (US) | 1985-09-11 | — | — | EP | disclosed |
| US-4242256-A | Synthesis of peptide analogues | SHARPE ROBERT (GB) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414699-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | PRKDC, DPM1, MMP8 | SLC7A5 3788/4885OPRD1 4854/4885OPRM1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.